HK1246367A1 - 转移性疾病的基因标记预测 - Google Patents

转移性疾病的基因标记预测 Download PDF

Info

Publication number
HK1246367A1
HK1246367A1 HK18105968.7A HK18105968A HK1246367A1 HK 1246367 A1 HK1246367 A1 HK 1246367A1 HK 18105968 A HK18105968 A HK 18105968A HK 1246367 A1 HK1246367 A1 HK 1246367A1
Authority
HK
Hong Kong
Prior art keywords
metastatic disease
gene signatures
signatures predictive
expression level
cancer
Prior art date
Application number
HK18105968.7A
Other languages
English (en)
Chinese (zh)
Inventor
Steven Walker
Laura Hill
Andrena MCCAVIGAN
Sinead DONEGAN
Timothy Davison
Richard Kennedy
Denis Paul Harkin
Bethanie PRICE
Original Assignee
Almac Diagnostic Services Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostic Services Limited filed Critical Almac Diagnostic Services Limited
Publication of HK1246367A1 publication Critical patent/HK1246367A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18105968.7A 2015-06-17 2016-06-17 转移性疾病的基因标记预测 HK1246367A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
GB201510684 2015-06-17
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
HK1246367A1 true HK1246367A1 (zh) 2018-09-07

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105968.7A HK1246367A1 (zh) 2015-06-17 2016-06-17 转移性疾病的基因标记预测

Country Status (8)

Country Link
US (1) US20210254166A1 (enExample)
EP (1) EP3310927B1 (enExample)
JP (1) JP2018527886A (enExample)
CN (1) CN108513587A (enExample)
CA (1) CA2989388A1 (enExample)
GB (1) GB201510684D0 (enExample)
HK (1) HK1246367A1 (enExample)
WO (1) WO2016203262A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
JP7741104B2 (ja) * 2020-01-21 2025-09-17 ジェニアリス インコーポレイテッド 分子バイオマーカーデータセット全体にわたる予測シグネチャの堅牢性および転用可能性の評価
CA3174199A1 (en) 2020-04-09 2021-10-14 Ashraf Hafez Predicting likelihood and site of metastasis from patient records
TW202216996A (zh) 2020-06-29 2022-05-01 美商Ionis製藥公司 調節ｐｌｐ１之化合物及方法
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN117741155A (zh) * 2023-11-21 2024-03-22 中国药科大学 Abcc4蛋白用于制备前列腺癌诊断试剂盒的用途
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
NZ582941A (en) 2007-08-13 2012-05-25 Almac Diagnostics Ltd A 3' -based sequencing approach for microarray manufacture
DK2376215T3 (en) * 2008-12-11 2019-01-28 Univ California FILTER CONE
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
CA2836277A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer

Also Published As

Publication number Publication date
US20210254166A1 (en) 2021-08-19
WO2016203262A2 (en) 2016-12-22
CA2989388A1 (en) 2016-12-22
JP2018527886A (ja) 2018-09-27
EP3310927B1 (en) 2021-05-19
EP3310927A2 (en) 2018-04-25
CN108513587A (zh) 2018-09-07
WO2016203262A3 (en) 2017-01-26
GB201510684D0 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
JO3681B1 (ar) استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
WO2014144121A3 (en) Classification and actionability indices for lung cancer
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
BR112016006635A2 (pt) método de seleção dentre uma pluralidade de planos de tratamento para tratar um tumor, e, produto de computador
WO2016077366A8 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
WO2014145751A3 (en) Targeted therapies for cancer
EP3495502A3 (en) Biomarkers for premature birth
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
UA116982C2 (uk) Спосіб виявлення трансгенної кукурудзи dp-004114-3
WO2013169771A3 (en) Methods and compositions for the prognosis and treatment of relapsed leukemia